Times of India |
Smartphone app to predict heart attack risk
Times of India The app analyses a patient’s heart rate, blood pressure, kidney function, severity of original attack and history of heart failure to get an accurate assessment of the potential risk of repeat heart attack and the type of treatment required, ‘The Times … |
Amgen, Cytokinetics heart failure drug misses goal in study – Reuters India
Amgen, Cytokinetics heart failure drug misses goal in studyReuters IndiaAMSTERDAM (Reuters) – An experimental heart failure drug from Amgen and Cytokinetics missed its goal of improving shortness of breath in a mid-stage clinical trial, leaving its fut…
Sunderland family collect organ donor award in memory of son – Sunderland Echo
Sunderland Echo |
Sunderland family collect organ donor award in memory of son
Sunderland Echo Ian and Sue will travel to St James’ Palace in London on Wednesday, September 18, for the UK Organ Donation Awards where they will collect the award in Paul’s memory. Paul’s heart, kidneys, lungs and liver were all donated to people waiting for organs. |
Cytokinetics, Amgen: Heart Failure Drug Misses Primary Endpoint – NASDAQ
Cytokinetics, Amgen: Heart Failure Drug Misses Primary EndpointNASDAQCytokinetics Inc. ( CYTK ) and Amgen Inc. ( AMGN ) said results from a mid-stage trial for their experimental drug for acute heart failure failed to meet its primary endpoint. Shares …
UPDATE 1-Amgen, Cytokinetics heart failure drug misses goal in study – Reuters UK
UPDATE 1-Amgen, Cytokinetics heart failure drug misses goal in studyReuters UKAMSTERDAM, Sept 3 (Reuters) – An experimental heart failure drug from Amgen and Cytokinetics missed its goal of improving shortness of breath in a mid-stage clinical trial, l…
UPDATE 1-Amgen, Cytokinetics heart failure drug misses goal in study – Reuters
UPDATE 1-Amgen, Cytokinetics heart failure drug misses goal in studyReutersAMSTERDAM, Sept 3 (Reuters) – An experimental heart failure drug from Amgen and Cytokinetics missed its goal of improving shortness of breath in a mid-stage clinical trial, leav…
Puducherry sets sights on organ donation and awareness – The Hindu
The HinduPuducherry sets sights on organ donation and awarenessThe HinduHave you thought about donating your eyes? If not, you may want to consider signing up to help the plight of the 300 odd people in Puducherry who are waiting for corneal transplant…
Cardiac Resynchronization Therapy Fails for Certain Heart Failure Patients – HealthCanal.com
|
Cardiac Resynchronization Therapy Fails for Certain Heart Failure Patients
HealthCanal.com COLUMBUS, Ohio – Researchers announced today that an attempt to expand cardiac resynchronization therapy (CRT) to include more patients with heart failure has failed and the international clinical trial ended early to prevent potential harm to patients. Cardiac Resynchronization Therapy offers no benefit beyond ICD therapy in …Medical Xpress ECHO-CRT: Resynchronization no help, may be harmful in narrow-QRS heart …TheHeart.Org Electromagnets guide heart device implantation, reduce radiation exposureWebWire (press release) MedPage Today –Forbes all 5 news articles » |
Amgen drug misses endpoint in acute heart failure trial – PMLiVE
Amgen drug misses endpoint in acute heart failure trialPMLiVEA drug in development by Amgen and Cytokinetics to treat symptoms of heart failure has missed its primary endpoint in a phase II trial. During the ATOMIC-AHF trial involving 613 patients with…
More data backs Novartis' serelaxin in heart failure – PMLiVE
Business Recorder |
More data backs Novartis’ serelaxin in heart failure
PMLiVE Momentum continues to build behind Novartis’ heart failure candidate serelaxin, with new data from the European Society of Cardiology (ESC) meeting cementing its position as a blockbuster-in-waiting. A new analysis of data from the RELAX-AHF study has … Novartis heart failure drug effective across patient groupsReuters India Novartis’ serelaxin (RLX030) improved symptoms and mortality across multiple …ITNews Efficacy Of Novartis AG (ADR) (NYSE:NVS) For Heart FailuresPR Carbon (press release) |